The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

Table 2

The cut-offs, sensitivity, and specificity of the metabolite concentrations, their ratios, and ADCmean values in a GBM relapse. AUC, area under the curve for each ROC analysis with appropriate statistical significance ().

	AUC (95% CI)		Cut-off	Sensitivity	Specificity
Metabolite/MRS			[mM]
tCho	0.532 (0.325; 0.740)	0.739	≤2.9	69.4	41.7
tNAA	0.970 (0.926; 1.000)	<0.001	≤1.5	75.0	100.0
tCr	0.613 (0.426; 0.801)	0.243	≤2.6	55.6	66.7
Lip + Lac	0.782 (0.574; 0.991)	0.004	≥4.8	100.0	66.7
tCho/tNAA	0.991 (0.970; 1.000)	<0.001	≥1.4	100.0	91.7
tCho/tCr	0.597 (0.388; 0.806)	0.317	≥0.7	83.3	41.7
tNAA/tCr	0.926 (0.786; 1.000)	<0.001	≤0.7	94.4	91.7
Lip + Lac/tCr	0.782 (0.574; 0.990)	0.004	≥1.9	91.7	75.0
ADC/DWI			[10^−6 mm^2/s]
ADCmean	1.000 (1.000; 1.000)	<0.001	≤1300	100.0	100.0